Patients, their loved ones, and practitioners can call the Visudyne hotline at 1-877-873-2826 (TREAT-AMD), Monday through Friday, 9 AM to 8 PM, ET. The Visudyne mySight™ Program—a FREE information-and-support program just for Visudyne patients and their loved ones—is another good source. Click here to learn more about mySight now.

In April 2000, the Food and Drug Administration (FDA) approved Visudyne therapy, the first drug treatment for the most serious form of "wet" age-related macular degeneration (AMD). Visudyne therapy, a form of photodynamic therapy, brings together a light-activated drug (Visudyne) and the use of a non-thermal ("cold") laser. The laser activates the drug in a targeted area of the eye, producing a reaction that destroys abnormal, leaky blood vessels.

After the initial therapy, I will examine your eyes approximately every 3 months to gauge your response to the previous therapy. Since leakage and bleeding often recur and the abnormal vessels often return with this persistent disease, we must plan to give you Visudyne therapy every 3 months, until the bleeding and leakage are no longer present. Visudyne therapy causes the skin and eyes to temporarily become sensitive to light (photosensitivity).

Visudyne therapy is a simple intravenous infusion into the arm followed by the application of a cool laser light to the eye. The application of light does not cause any pain in the eye. Other than the initial prick delivered by injection, patients are not likely to experience any pain. Some patients (10%-30%) have experienced side effects such as injection site reactions, back pain during infusion, and blurring, decreased sharpness, and gaps in vision.

Visudyne therapy is not for everyone. People who have an abnormal sensitivity to light (a condition called porphyria) and those with allergies to any of the ingredients should not receive Visudyne. (Your doctor has a list of ingredients in Visudyne.) Check with your doctor or healthcare professional to see if you might be allergic to any component of Visudyne therapy. Only your doctor can determine if Visudyne is right for you.

When preparing for your therapy, remember Visudyne therapy causes your skin and eyes to become temporarily sensitive to light. Be sure to bring the following items to your appointment: After your treatment, your eyes and skin will be sensitive to bright light and direct sunlight for 5 days. You should wear a wristband to remind yourself of this photosensitivity, and follow precautions such as avoiding: You should not stay in the dark.

Visudyne is the first drug therapy to become available for patients with a certain form of age-related macular degeneration (AMD). It is used in the treatment of patients with the type of AMD known as predominantly classic subfoveal wet AMD. The generic, or chemical, name for Visudyne is verteporfin (ver-te-POOR-fin). Only a qualified eye care professional can determine if Visudyne therapy is right for you.

Yes. Studies have shown that patients who complete a full course of Visudyne therapy are more likely to preserve their vision than those who have no therapy. There is currently no therapy that will cure AMD. There is no cure for AMD. While Visudyne helps destroy existing abnormal blood vessels that can leak and damage sight, there is currently no therapy that will restore sight that has already been lost. Therefore, patients and their loved ones need to have realistic expectations for therapy.

Yes, email info@media-innovations.ltd.uk and we can send you a Calipso pack with information for you and your practitioner.

Cardiovascular diseases today are the leading cause of death throughout the world. One of the most prevalent forms of heart disease is Congestive Heart Failure (CHF). In the U.S. alone, an estimated five million people suffer from CHF, with another 550,000 new cases diagnosed each year. We estimate that as many as 100,000 patients per year in the U.S. could be helped by this new treatment option.

Coverage for psychiatric services varies by health insurance plans. Some plans have a "carve-out" for mental health care, meaning services are covered by a separate organization that the patient must contact directly. You should call your insurance provider or check your benefits manual to confirm if mental health services are covered in this department before calling our Intake Coordinators.

Not all patients who have an inner ear disorder need vestibular rehabilitation. Patients who do not demonstrate a spontaneous resolution of symptoms such as dizziness and disequilibrium within six months of their onset may benefit from therapy. In these patients, the central nervous system seems unable to adequately compensate for the inner ear deficit.

Virtually painless, Visudyne therapy is typically performed in a doctor's office on an outpatient basis. You will be unusually sensitive to light for 5 days following Visudyne therapy, so preparing for treatment is key. Your eyecare specialist will give you a list of instructions to follow before and after therapy to minimize the risk of complications. Visudyne therapy is typically given about every 3 months and as many times as needed to prevent the regrowth of abnormal vessels.

Visudyne is a multicourse therapy. Follow-up evaluations are recommended at 3-month intervals to determine if subsequent treatment is required. Usually several treatments are given over a period of time. In clinical trials for AMD, patients treated with Visudyne received 3.4 treatments in the first year and 2.0 treatments the second year.

Finding out more about the health of your eye and your vision correction needs is your first step toward better eyesight. Contact Dr. Kornmehl's office at 1-877-870-2010 for an appointment and personal consultation. If your vision's refractive error falls within the range for laser surgery, more tests can be performed to determine whether you are a candidate. This information will help you determine your best options for vision correction.

Opportunities for change and variety characterize the outstanding range of career options in occupational therapy. You will be welcomed by employers such as public schools, rehabilitation hospitals, mental health centers, nursing home, physician practices, and home health agencies. As your career progresses, you will want to consider advancement opportunities in management, specialization, teaching, research, or private practice.

We encourage potential patients to seek referrals through their primary care provider (PCP) or local radiation oncology specialists. If these individuals are not familiar with proton therapy an inquiry line 617-724-1680 and e-mail address InformationRadOnc@partners.org can be used to directly seek specific contact information.

Yes and no. Each laser has different wavelengths and power levels that can be used safely during different periodontal procedures. However, damage to periodontal tissues can result if an inappropriate wavelength and/or power level is used during a periodontal procedure. this time, there is insufficient evidence to suggest that any specific laser wavelength is superior to the traditional treatment methods of the common periodontal diseases, such as periodontitis.

Approximately 60% of cancer patients receive radiation therapy. Radiation therapy may be prescribed as the only treatment for the patient, or it may be prescribed in combination with surgery and/or chemotherapy.

Patients who have been prescribed telithromycin and are not suffering side effects such as jaundice should continue taking their medicine as prescribed. Patients who notice any yellowing of their eyes or skin or other problems like blurry vision should contact their healthcare providers.

Typically, in homeopathy, patients have a lengthy first visit, during which the provider takes an in-depth assessment of the patient. This is used to guide the selection of one or more homeopathic remedies. During followup visits, patients report how they are responding to the remedy or remedies, which helps the practitioner make decisions about further treatment.

First, Visudyne is injected into the bloodstream, usually through a vein in the patient's arm. The drug is quickly absorbed by the abnormal blood vessels in the back of the eye that cause sight loss in wet AMD. Second—a short time after the drug has been given—a cold laser is shone into the affected area of the eye for exactly 83 seconds. This activates the drug and produces a reaction that destroys the abnormal blood vessels.

Visudyne is indicated for the treatment of a specific type of abnormal blood vessels that grow in the center of the macula—the part of the eye responsible for central vision—due to age-related macular degeneration, pathologic myopia, or presumed ocular histoplasmosis. I provide Visudyne for patients who I believe are appropriate candidates for the therapy based on these indications and my experience.

If you receive Visudyne therapy, your eyes and skin will be sensitive to bright light and direct sunlight for 5 days. During this time, you should wear a wristband to remind yourself about the possibility of photosensitivity and the need to follow the precautions for things to avoid: You should not stay in the dark, however, because exposing your skin to normal indoor light helps to remove the drug from the skin.

In clinical trials, a substantial decrease in vision occurred in 1% to 5% of patients within the first week of treatment, with partial recovery in some patients. Other potential problems include injection site reactions, back pain during infusion, and visual disturbances—including blurring, decreased sharpness, and gaps in vision.

Yes, it is possible to treat interference fields painlessly without needles. The Tenscam®, a hand-held electronic device, pointed at the interference field from a distance of 18 inches for about two minutes, seems to be as effective as procaine injections.